BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
31 Outubro 2023 - 9:00AM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”),
a global clinical-stage biopharmaceutical company focused on using
a groundbreaking technology platform for drug discovery and
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs, today announced that the
Company and Professor Kathryn M. Eisenmann of the University of
Toledo College of Medicine presented a poster on the potent
efficacy of plinabulin in a derived patient model of glioblastoma,
a disease of high unmet need at the 2023 AACR Special Conference in
Cancer Research: Brain Cancer on Oct 20th, 2023 at Minneapolis, MN.
Professor Eisenmann’s research interests include glioblastoma
invasion programs and developing small molecule therapeutics that
target cytoskeleton networks. She has built a comprehensive
glioblastoma patient cell line repository of more than 6 dozen
samples of primary and therapy-resistant recurrent tumors.
The presentation demonstrated the monotherapy activity of
plinabulin at 10-30 nM at killing 3D neurospheres from five
glioblastoma multiforme (GBM) patient-derived primary cell lines
and therapy-resistant cell lines. Plinabulin was confirmed to have
anti-proliferative properties in GBM at therapeutic concentrations.
Plinabulin blocked GBM patient-derived sphere invasion, while
significantly decreasing GBM cell survival and extension of
microtubules. This model is directly relevant to the recurrence of
glioblastoma after resection, and plinabulin killed these cells and
stopped the spread of the tumor.
“Recent investigation into targeted therapies has failed to
address invasion and cytoskeleton based GBM therapy resistance.
Plinabulin, which can pass blood brain barrier, is a differentiated
microtubule-targeting and immune-oncology agent. Plinabulin had
shown single agent activity in transgenic GBM animal model with
survival benefit compared to placebo,” said Dr. Kathryn Eisenmann.
“This presentation further demonstrates plinabulin’s potential in
brain tumor, which is severely unmet medical needs.”
About BeyondSpringBeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focusing on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly and Company. Learn
more by visiting https://beyondspringpharma.com.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024